TP53 and acute myeloid leukemia: The clinical characteristics of these groups were generally well-matched, though patients with CBF AML were significantly younger (p<0.01, t-test) with higher white blood cell count (p<0.01, t-test) and peripheral blast percentages (p<0.01, t-test) than TP53-mutated AML.